share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Elston George

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Elston George

EyePoint Pharmaceuticals | 4:持股變動聲明-高管 Elston George
美股sec公告 ·  05/28 22:38
Moomoo AI 已提取核心訊息
George Elston, the Chief Financial Officer of EyePoint Pharmaceuticals, completed a transaction involving the company's common stock on May 25, 2024. Elston exercised options to acquire 7,500 shares at no cost and subsequently sold 3,627 shares at a price of $11.16 per share. The sale resulted in a total market value of $40,477.32. Following these transactions, Elston's direct holdings in EyePoint Pharmaceuticals common stock amounted to 47,480 shares.
George Elston, the Chief Financial Officer of EyePoint Pharmaceuticals, completed a transaction involving the company's common stock on May 25, 2024. Elston exercised options to acquire 7,500 shares at no cost and subsequently sold 3,627 shares at a price of $11.16 per share. The sale resulted in a total market value of $40,477.32. Following these transactions, Elston's direct holdings in EyePoint Pharmaceuticals common stock amounted to 47,480 shares.
EyePoint Pharmicals首席財務官喬治·埃爾斯頓於2024年5月25日完成了一項涉及該公司普通股的交易。埃爾斯頓行使期權免費收購了7,500股股票,隨後以每股11.16美元的價格出售了3,627股股票。此次出售的總市值爲40,477.32美元。這些交易之後,埃爾斯頓直接持有的EyePoint Pharmicals普通股爲47,480股。
EyePoint Pharmicals首席財務官喬治·埃爾斯頓於2024年5月25日完成了一項涉及該公司普通股的交易。埃爾斯頓行使期權免費收購了7,500股股票,隨後以每股11.16美元的價格出售了3,627股股票。此次出售的總市值爲40,477.32美元。這些交易之後,埃爾斯頓直接持有的EyePoint Pharmicals普通股爲47,480股。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息